Coherus BioSciences, Inc.
CHRS Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
CHRS Income Statement
CHRS Balance Sheet
CHRS Cash Flow
Recent trades of CHRS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Shri Thanedar House / D | Sale $15,001 - $50,000 | Jan. 23, 2023 |
CHRS Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
CHRS Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
CHRS Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CHRS's directors and management
Government lobbying spending instances
-
$45,000 Sep 26, 2024 Issue: Government Issues Health Issues
-
$87,500 Sep 26, 2024 Issue: Government Issues Health Issues
-
$87,500 Apr 22, 2024 Issue: Government Issues Health Issues
-
$45,000 Jan 29, 2024 Issue: Intelligence Defense
-
$10,000 Jan 22, 2024 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$40,000 Jan 20, 2024 Issue: Pharmacy Health Issues Medicare/Medicaid
-
$45,000 Jan 10, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Dec 31, 2023 Issue: Pharmacy
-
$275,000 Oct 20, 2023 Issue: Government Issues Health Issues
-
$275,000 Jul 19, 2023 Issue: Government Issues Health Issues
-
$275,000 Apr 19, 2023 Issue: Government Issues Health Issues
-
$275,000 Jan 19, 2023 Issue: Government Issues Health Issues
-
$250,000 Oct 18, 2022 Issue: Government Issues Health Issues
-
$250,000 Jul 14, 2022 Issue: Government Issues Health Issues
-
$200,000 Mar 29, 2022 Issue: Government Issues Health Issues
-
$160,000 Jan 21, 2022 Issue: Government Issues Health Issues
-
$130,000 Oct 22, 2021 Issue: Government Issues Health Issues
-
$100,000 Aug 13, 2021 Issue: Health Issues Government Issues
-
$100,000 Apr 20, 2021 Issue: Government Issues Health Issues
-
$75,000 Jan 04, 2021 Issue: Health Issues Government Issues
-
$50,000 Nov 04, 2020 Issue: Health Issues Government Issues
-
$60,000 Jul 03, 2020 Issue: Pharmacy
-
$60,000 Apr 12, 2020 Issue: Pharmacy
-
$60,000 Jan 08, 2020 Issue: Pharmacy
-
$60,000 Oct 13, 2019 Issue: Pharmacy
-
$60,000 Jul 11, 2019 Issue: Pharmacy
-
$60,000 Apr 09, 2019 Issue: Pharmacy
-
$60,000 Jan 13, 2019 Issue: Pharmacy
-
$60,000 Oct 15, 2018 Issue: Pharmacy
-
$60,000 Jan 02, 2018 Issue: Pharmacy Health Issues Medicare/Medicaid
-
$80,000 Dec 31, 2017 Issue: None
-
$120,000 Oct 11, 2017 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Budget/Appropriations
-
$120,000 Jul 12, 2017 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations
-
$120,000 Apr 14, 2017 Issue: Health Issues Copyright/Patent/Trademark Budget/Appropriations Medicare/Medicaid
-
$120,000 Dec 19, 2016 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Budget/Appropriations
-
$120,000 Oct 17, 2016 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations
-
$120,000 Jul 14, 2016 Issue: Medicare/Medicaid Budget/Appropriations Copyright/Patent/Trademark Health Issues
-
$120,000 Apr 18, 2016 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$40,000 Oct 19, 2015 Issue: Health Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Systems and methods for producing sterile injection devices Sep. 12, 2023
-
Patent Title: Stable aqueous formulations of aflibercept Jun. 06, 2023
-
Patent Title: Stable protein compositions and methods of their use Feb. 21, 2023
-
Patent Title: Method of filling a container with no headspace Feb. 14, 2023
-
Patent Title: Stable aqueous formulations of aflibercept Aug. 30, 2022
-
Patent Title: Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy Aug. 02, 2022
-
Patent Title: Methods for making recombinant proteins Jul. 26, 2022
-
Patent Title: Ppary agonist for treatment of progressive supranuclear palsy Feb. 22, 2022
-
Patent Title: High concentration formulations of adalimumab Jan. 25, 2022
-
Patent Title: Etanercept formulations stabilized with metal ions Oct. 05, 2021
-
Patent Title: Etanercept formulations stabilized with amino acids Sep. 28, 2021
-
Patent Title: Method of filling a container with no headspace Jul. 27, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield May. 11, 2021
-
Patent Title: Method of manufacturing a protein by perfusion in media with a low amino acid concentration May. 11, 2021
-
Patent Title: Etanercept formulations stabilized with sodium chloride May. 11, 2021
-
Patent Title: Method of reducing formation of etanercept aggregates or fragments Apr. 27, 2021
-
Patent Title: Method of reducing formation of etanercept aggregates or fragments Apr. 20, 2021
-
Patent Title: Stable aqueous etanercept composition Apr. 20, 2021
-
Patent Title: Correctly folded etanercept composition Apr. 13, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 16, 2021
-
Patent Title: Stable aqueous etanercept composition Jan. 12, 2021
-
Patent Title: Etanercept formulations exhibiting marked reduction in sub-visible particles Nov. 03, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Oct. 13, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 29, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 22, 2020
-
Patent Title: Etanercept formulations stabilized with xylitol Sep. 15, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 15, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 15, 2020
-
Patent Title: Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy Sep. 15, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 28, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 21, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 21, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 21, 2020
-
Patent Title: Stable aqueous formulations of adalimumab Jun. 23, 2020
-
Patent Title: Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy Feb. 11, 2020
-
Patent Title: Etanercept formulations stabilized with sodium chloride Dec. 03, 2019
-
Patent Title: Etanercept formulations stabilized with meglumine Nov. 26, 2019
-
Patent Title: Etanercept formulations stabilized with combinations of sugars and polyols Aug. 13, 2019
-
Patent Title: Etanercept formulations stabilized with amino acids May. 21, 2019
-
Patent Title: Methods of manufacturing stable aqueous formulations of adalimumab May. 14, 2019
-
Patent Title: Syringe containing stable aqueous formulations of adalimumab May. 14, 2019
-
Patent Title: Etanercept formulations stabilized with xylitol Feb. 26, 2019
-
Patent Title: Stable aqueous formulations of adalimumab Feb. 19, 2019
-
Patent Title: Stable aqueous formulations of adalimumab Feb. 05, 2019
-
Patent Title: Stable aqueous formulations of adalimumab Dec. 25, 2018
-
Patent Title: Stable aqueous formulations of adalimumab Dec. 25, 2018
-
Patent Title: Stable aqueous formulations of adalimumab Dec. 18, 2018
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of CHRS in WallStreetBets Daily Discussion
CHRS News
Recent insights relating to CHRS
CNBC Recommendations
Recent picks made for CHRS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CHRS
CHRS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CHRS Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More